Add this topic to your myFT Digest for news straight to your inbox
Report from Nuffield Trust health think-tank highlights impact of leaving EU on medicine supply chains
Michel Demaré in FT hits out at ISS and Glass Lewis for applying ‘double standards’ after they opposed CEO pay package
Almost 36 per cent of shareholders voted against a £1.8mn rise for the pharma group’s boss
WuXi AppTec and WuXi Biologics under threat from proposed national security legislation
Xylazine, commonly used to sedate animals, found cut with heroin, counterfeit tablets and cannabis vapes, study finds
GQG Partners argues that pharma group has performed strongly under long-serving chief
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Novo Nordisk and Eli Lilly, plus a clutch of rivals, aim to cut side effects while treating obesity-linked diseases
Shareholder advisory groups say potential £18.7mn payout is excessive
Record shortages of common drugs have countries scrambling for alternatives while patients skip treatments
Danish group seeks to branch out from diabetes and weight loss drugs with Cardior acquisition
Funding needed to drive innovation and make therapies available to all, says co-discoverer Jennifer Doudna
Ruth McKernan aims to make country a hub for research into the condition and accelerate development of new drugs
Acquisition gives pharmaceutical group mid-stage asset to challenge Novartis in new form of cancer care
Drugmaker releases promising trial results for a pill and expects to enter China this year
Nice fails to approve Enhertu due to value-for-money concerns despite it being recommended in Scotland
US group hunts for outsourcers to lift production of Zepbound as it takes on Danish group’s Wegovy blockbuster
GHO Capital has put contract research group FairJourney Biologics up for sale
Research shows urgent need for policies to encourage weight loss and cut disease risk
US biotech group’s data suggests dominance of Novo Nordisk and Eli Lilly in the anti-obesity segment could be challenged in a few years
German pharma group finds no unexpected side effects during trial, including at higher doses
Baseimmune aims to predict future pathogen mutations to create jabs that will be effective for longer
Virginia-based drugmaker says switch would attract more US investors
Best-selling Tagrisso drug slows progression of most common form of the disease at an early stage
The coffers of Novo Nordisk’s controlling shareholder have been boosted by diabetes and weight loss drugs
International Edition